BioXcel Therapeutics, Inc. financial data

Symbol
BTAI on Nasdaq
Industry
Pharmaceutical Preparations
Location
555 Long Wharf Drive, New Haven, CT
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 6, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 252 % -60.3%
Quick Ratio 7.28 % +19.9%
Debt-to-equity -232 % -220%
Return On Equity 177 %
Return On Assets -134 % -27.2%
Operating Margin -4.56K %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 40.7M shares +39.2%
Common Stock, Shares, Outstanding 40.4M shares +38%
Entity Public Float 135M USD -46.2%
Common Stock, Value, Issued 40K USD +37.9%
Weighted Average Number of Shares Outstanding, Basic 40.3M shares +37.9%
Weighted Average Number of Shares Outstanding, Diluted 40.3M shares +37.9%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 2.4M USD +142%
Research and Development Expense 49M USD -55.3%
General and Administrative Expense 55.5M USD +66.6%
Costs and Expenses 112M USD -43%
Operating Income (Loss) -110M USD +43.9%
Nonoperating Income (Expense) 62K USD
Net Income (Loss) Attributable to Parent -108M USD +46.9%
Earnings Per Share, Basic -3.56 USD/shares +50%
Earnings Per Share, Diluted -3.56 USD/shares +50%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 56.3M USD -55.9%
Inventory, Net 2.68M USD +39.2%
Other Assets, Current 1.64M USD -64.6%
Assets, Current 64.2M USD -53.6%
Property, Plant and Equipment, Net 629K USD -33.2%
Operating Lease, Right-of-Use Asset 538K USD -35.5%
Other Assets, Noncurrent 87K USD 0%
Assets 65.4M USD -53.3%
Accounts Payable, Current 13.3M USD +18.3%
Employee-related Liabilities, Current 2.08M USD -48.4%
Accrued Liabilities, Current 13.5M USD -29.5%
Liabilities, Current 27.3M USD -21.5%
Operating Lease, Liability, Noncurrent 256K USD -58.5%
Liabilities 140M USD +4.1%
Retained Earnings (Accumulated Deficit) -626M USD -20.8%
Stockholders' Equity Attributable to Parent -74.3M USD -1367%
Liabilities and Equity 65.4M USD -53.3%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -17.7M USD +66.2%
Net Cash Provided by (Used in) Financing Activities 26.6M USD +10.3%
Net Cash Provided by (Used in) Investing Activities -120K USD +62%
Common Stock, Shares Authorized 200M shares +100%
Common Stock, Shares, Issued 40.4M shares +38%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 8.92M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 56.3M USD -55.9%
Deferred Tax Assets, Valuation Allowance 174M USD +46.7%
Operating Lease, Liability 617K USD -35%
Depreciation 312K USD -4.59%
Payments to Acquire Property, Plant, and Equipment 120K USD -62%
Lessee, Operating Lease, Liability, to be Paid 647K USD -36.8%
Property, Plant and Equipment, Gross 1.98M USD 0%
Operating Lease, Liability, Current 361K USD +8.74%
Lessee, Operating Lease, Liability, to be Paid, Year Two 65K USD -83.4%
Lessee, Operating Lease, Liability, to be Paid, Year One 391K USD +2.63%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 30K USD -60%
Lessee, Operating Lease, Liability, to be Paid, Year Three 65K USD -83.4%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 65K USD -83.4%
Additional Paid in Capital 551M USD +5.28%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 309K USD +50%
Deferred Tax Assets, Net of Valuation Allowance 197K USD -23%
Share-based Payment Arrangement, Expense 12.1M USD -39.6%
Interest Expense 13.6M USD +17.1%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%